8-K: Elicio Therapeutics Announces Positive Updated Results for ELI-002 Cancer Vaccine at ESMO Immuno-Oncology Congress

Elicio Therapeutics presented updated Phase 1 results for its ELI-002 cancer vaccine, showing a 16.3-month median recurrence-free survival and a 28.9-month median overall survival in patients with mKRAS-driven cancers.

Summary

• Elicio Therapeutics presented updated results from its Phase 1 AMPLIFY-201 study of ELI-002, a cancer vaccine targeting KRAS mutations.
• The study included 25 patients with mKRAS-driven pancreatic or colorectal cancer who had residual disease after standard treatment.
• The updated data showed a median recurrence-free survival (mRFS) of 16.3 months and a median overall survival (mOS) of 28.9 months for the full study cohort.
• Patients with above-median T cell responses had a mRFS that was not reached, while those with below-median T cell responses had a mRFS of 4.0 months.
• The mOS was identical for the full study cohort and the pancreatic cancer subgroup, and it compared favorably to historical data.
• The ELI-002 vaccine was well-tolerated, with no serious adverse events reported.
• The company is also conducting a Phase 2 trial of a 7-peptide formulation of ELI-002, with an interim analysis expected in the first half of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data, with strong efficacy and safety results. The company is also progressing its pipeline and has secured funding into the second quarter of 2025. The sentiment is very positive, but there are still risks associated with clinical development and funding.

Positives

• The ELI-002 vaccine showed promising efficacy data with a 16.3-month median recurrence-free survival and a 28.9-month median overall survival.
• The vaccine demonstrated a strong correlation between T cell response and clinical outcomes, with patients having above-median T cell responses showing significantly better results.
• The ELI-002 vaccine was well-tolerated, with no serious adverse events reported.
• The company has completed enrollment in a Phase 2 trial of the 7-peptide formulation of ELI-002, with an interim analysis expected in the first half of 2025.
• The vaccine is designed to target multiple common KRAS mutations, potentially benefiting a large patient population.
• The AMP technology used in the vaccine is designed to enhance the immune response by targeting the lymph nodes.

Negatives

• The study was a Phase 1 trial with a relatively small sample size of 25 patients.
• The median RFS for patients with below median T cell response was only 4.01 months.
• The study was open-label, which may introduce bias.
• The study population was limited to patients with mKRAS-driven pancreatic and colorectal cancer with minimal residual disease.

Risks

• The company's ability to obtain funding to advance the development of ELI-002 is a risk.
• The timing of the availability of data from clinical trials is uncertain.
• The company's ability to successfully collaborate with existing collaborators or enter into new collaborations is a risk.
• The clinical utility, potential benefits, and market acceptance of the product candidates are not guaranteed.
• The company's ability to protect its intellectual property position is a risk.
• The company's estimates regarding future revenue, expenses, capital requirements, and need for additional financing are subject to change.

Future Outlook

The company anticipates Phase 3 readiness in the first quarter of 2026 and plans to initiate a Phase 1B study in colorectal cancer and combination studies. They also plan to advance ELI-007 and ELI-008 into Phase 1 trials and seek partnerships for ELI-002 and ELI-004.

Management Comments

• Christopher Haqq, M.D., Ph.D., stated that the results exceeded expectations based on historical cohorts of similar populations with KRAS-mutant pancreatic and colorectal cancers.
• Management highlighted the strong correlation between T cell response, tumor biomarker reductions, and reduced risk of progression or death.

Industry Context

The announcement is relevant to the broader trend of developing targeted immunotherapies for cancer, particularly those addressing KRAS mutations, which are common drivers of solid tumors. The company's lymph node-targeting AMP technology is a differentiated approach compared to other vaccine development efforts.

Comparison to Industry Standards

• The median overall survival of 28.9 months in the ELI-002 study compares favorably to historical data for MRD+ PDAC, which is around 17 months from resection.
• The company highlights that other mKRAS therapies, such as LUMAKRAS and KRAZATI, only target the G12C mutation and are subject to resistance mechanisms.
• The company also notes that personalized neoantigen vaccines have manufacturing challenges and are costly, while ELI-002 is an off-the-shelf product.
• The company compares its approach to Moderna/Merck's KeyNote-942 and BioNTech/Roche's Autogene Cevumeran, noting that those do not have lymph node targeting and have manufacturing challenges.

Stakeholder Impact

• Shareholders will likely view the positive clinical data favorably.
• Patients with mKRAS-driven cancers may benefit from this new treatment option.
• Employees may be motivated by the positive results and the company's progress.
• Potential partners may be interested in collaborating with the company.

Next Steps

• The company will have a Type B meeting with the FDA to discuss the Phase 3 study design.
• An interim analysis of the Phase 2 trial is expected in the first half of 2025.
• An end of Phase 2 FDA meeting is expected in the second half of 2025.
• The company anticipates Phase 3 readiness in the first quarter of 2026.
• The company plans to initiate a Phase 1B study in colorectal cancer and combination studies.
• The company plans to advance ELI-007 and ELI-008 into Phase 1 trials.
• The company will seek partnerships for ELI-002 and ELI-004.

Key Dates

Keywords

ELI-002, cancer vaccine, mKRAS, immunotherapy, lymph node targeting, pancreatic cancer, colorectal cancer, T cell response, recurrence-free survival, overall survival, AMP technology